Patterns of oral anticoagulation use with cardioversion in clinical practice. Issue 8 (26th June 2020)

• Record Type: Journal Article
• Authors: Geurink, Kyle; Holmes, DaJuanicia; Ezekowitz, Michael D; Pieper, Karen; Fonarow, Gregg; Kowey, Peter R; Reiffel, James A; Singer, Daniel E; Freeman, James; Gersh, Bernard J; Mahaffey, Kenneth W; Hylek, Elaine M; Naccarelli, Gerald; Piccini, Jonathan P; Peterson, Eric D; Pokorney, Sean D
• Is Part Of: Heart. Volume 107:Issue 8(2021)
• Page Start: 642
• Page End: 649
• Publication Date: 2020-06-26
• Subjects: atrial fibrillation -- electrocardiography; Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2019-316315
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversion. Methods: Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II, patients with AF who had a cardioversion, follow-up data and an AF diagnosis within 6 months of enrolment were identified retrospectively. Clinical outcomes were compared for patients receiving a NOAC or VKA for 1 year following cardioversion. Results: Among 13 004 patients with AF, 2260 (17%) underwent cardioversion. 1613 met the inclusion criteria for this analysis. At the time of cardioversion, 283 (17.5%) were receiving a VKA and 1330 (82.5%) a NOAC. A transoesophageal echocardiogram (TOE) was performed in 403 (25%) cardioversions. The incidence of stroke/transient ischaemic attack (TIA) at 30 days was the same for patients having (3.04 per 100 patient-years) or not having (3.04 per 100 patient-years) a TOE (p=0.99). There were no differences in the incidence of death (HR 1.19, 95% CI 0.62 to 2.28, p=0.61), cardiovascular hospitalisation (HR 1.02, 95% CI 0.76 to 1.35, p=0.91), stroke/TIA (HR 1.18, 95% CI 0.30 to 4.74, p=0.81) or bleeding-related hospitalisation (HR 1.29, 95% CI 0.66 to 2.52, p=0.45) at 1 year for patients treated with either a NOAC or VKA. Conclusions: Cardioversion was a low-risk procedure for patients treated with NOAC, and there were statistically similar rates of stroke/TIA 30 days after cardioversion as for patients treated with VKA. There were no statically significant differences in death, stroke/TIA or major bleeding at 1 year among patients treated with NOAC compared with VKA after cardioversion.